Johnson & Johnson today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results